Finoriq research workspace
Amneal Pharmaceuticals, Inc. (AMRX) SEC Filings & Filing Highlights
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures. Review AMRX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
- Company
- Amneal Pharmaceuticals, Inc. (AMRX)
- Ticker
- AMRX
- Market Cap
- $5.6B
- Latest Price
- $17.52
- Industry
- Biotech & Pharma
Amneal Pharmaceuticals, Inc. (AMRX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Amneal Pharmaceuticals, Inc. (AMRX).
| Event | Form | Date |
|---|---|---|
| AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSAMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS | 8-K2.02 | 2026-05-07 |
| Proposal 1: To elect the following director nominees to hold office until the 2027 Annual Meeti...Amneal Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 6, 2026. Each of th... | 8-K5.07 | 2026-05-07 |
| Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar LeaderAmneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader | 8-K7.01 | 2026-04-22 |
| Amneal Pharmaceuticals, Inc.: Securities issuanceAmneal Pharmaceuticals, Inc. filed a Form 8-K covering securities issuance | 8-K3.02 | 2026-04-22 |
| Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar LeaderAmneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader | 8-K2.02 | 2026-04-22 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.